Remove Article Remove DEA Remove History Remove Treatment
article thumbnail

DMT Therapy: Coming to a Clinic Near You?

Canna Law Blog

So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.” MDMA (Ecstasy) Nears FDA Approval for PTSD Treatment.

Therapy 88
article thumbnail

And Here We Go Again! NASDAQ Article: Forget Cannabis: Psychedelic Medicine Is the Better Investing Opportunity

Cannabis Law Report

Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment). In 2018, the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What is the Difference Between a Cannabis Recommendation and Cannabis Prescription

United Patients Group

Epidiolex, an FDA-approved medication containing CBD (cannabidiol), has been listed as Schedule 5 by the DEA since June 25th, 2019. The doctor who writes the prescription must be licensed and has to write it for a specific patient, as opposed to prescribing general instructions for treatment. Cannabis is a schedule 1 substance.

DEA 52
article thumbnail

Scientists Think the Synthetic Cannabinoids in Sativex Can Beat Brain Cancer

SpeedWeed

Sativex has played a significant role in marijuana history. Sativex (sold as nabiximols or Epidiolex in the United States) is manufactured by British company GW Pharmaceuticals, which received full federal approval in its home country for the drug back in 2010 for the treatment of multiple sclerosis. View original article.

article thumbnail

Final Phase of MDMA Clinical Trials Shows Drug Is 90% Effective at Treating PTSD

SpeedWeed

The subjects had been experiencing PTSD symptoms for an average of 14 years, and 84 percent had a history of developmental trauma. For 88% of people who receive this treatment, we can expect to see a treatment response. View original article.

article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history.

article thumbnail

MAPS Organization Granted $12.9 Million to Study Cannabis and PTSD •

SpeedWeed

Suicide among veterans is an urgent public health crisis, but it’s solvable if we invest in researching new treatments for pain, depression, and PTSD,” said Sisley in a press statement. MAPS Makes History. Results of this study showed evidence of the pros and cons to cannabis as a treatment for PTSD patients.